All EPIVINF partners gathered at the Palau Macaya in Barcelona to share the latest scientific results obtained. The EU-funded project aims to redefine approaches to immune response and therapeutics in viral pathogens.
The European project EPIVINF marked a significant milestone on November 22, 2023, as it celebrated its annual meeting at the Palau Macaya in Barcelona. Bringing together international partners from various scientific backgrounds, the event served as a crucial platform for exchanging insights and updates on the latest scientific outcomes.
Funded by the European Union, the EPIVINF project is dedicated to unraveling the intricate relationship between acute viral infections and the epigenetic regulation of host genes that govern immune control and neurological health. The project’s primary focus is on two major human viral pathogens, HIV and SARS-CoV-2, both of which impact millions of individuals worldwide and share common features requiring further exploration.
One of the key objectives of EPIVINF is to investigate how pre-existing epigenetic factors influence the immune response to vaccination. By delving into the epigenetic landscape, researchers aim to identify novel therapeutic targets and better comprehend the factors predisposing individuals to specific clinical symptoms associated with these viral infections.
The project is organized into 8 work packages, each addressing different aspects of the research goals. The annual meeting provided an opportunity for international partners to share updates, discuss progress, and foster collaboration.
“We are very pleased to have all our esteemed partners gathered here for the annual meeting” stated Christian Brander, EPIVINF coordinator and principal investigator at IrsiCaixa. “This occasion not only facilitates the exchange of knowledge but also strengthens the collaborative spirit essential for advancing our understanding of viral infections. We look forward to continued progress and sharing new updates with our dedicated partners in the near future”, he added.
